In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications

Nuclear Medicine and Biology

Volumn 29, Issue 4, 2002, Pages 431-442

  Milenic, Diane E ^a   Garmestani, Kayhan ^a   Chappell, Lara L ^a   Dadachova, Ekaterina ^a   Yordanov, Alexander ^a   Ma, Dangshe ^a   Schlom, Jeffrey ^a   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CHX A ; DOTA; Lu 177; PA DOTA; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177; ANTIBODY CONJUGATE; LUTETIUM 177; MACROCYCLIC COMPOUND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY I 125; PENTETIC ACID LU 177; RADIOISOTOPE; RADIOLIGAND; UNCLASSIFIED DRUG; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; 4 AMINOPHENYLETHYL 1,4,7,10 TETRAAZACYCLODECANE N,N',N'',N''' TETRAACETIC ACID; 4-AMINOPHENYLETHYL-1,4,7,10-TETRAAZACYCLODECANE-N,N',N'',N'''-TETRAACETIC ACID; ANILINE DERIVATIVE; DRUG DERIVATIVE; HETEROCYCLIC COMPOUND; ISOTHIOCYANIC ACID DERIVATIVE; LUTETIUM; N (2 AMINO 3 (4 ISOTHIOCYANATOPHENYL)PROPYL)CYCLOHEXANE 1,2 DIAMINE N,N',N',N'',N'' PENTAACETIC ACID; N-(2-AMINO-3-(4-ISOTHIOCYANATOPHENYL)PROPYL)CYCLOHEXANE-1,2-DIAMINE-N,N',N',N'',N''-PENTAACETIC ACID; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RETENTION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; ISOTOPE LABELING; MOUSE; NONHUMAN; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; COLON TUMOR; COMPARATIVE STUDY; DRUG SCREENING; METABOLISM; NUDE MOUSE; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; WHOLE BODY COUNTING;

ADENOCARCINOMA; ANILINE COMPOUNDS; ANIMAL; ANTIBODIES, MONOCLONAL; COLONIC NEOPLASMS; COMPARATIVE STUDY; FEMALE; HETEROCYCLIC COMPOUNDS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMAN; IMMUNOCONJUGATES; ISOTHIOCYANATES; LUTETIUM; MICE; MICE, NUDE; PENTETIC ACID; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; WHOLE-BODY COUNTING; XENOGRAFT MODEL ANTITUMOR ASSAYS; ANIMALS; HUMANS;

EID: 0035988205     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(02)00294-9     Document Type: Article

References (59)

1. 177Lu-CC49: A phase I/II study
2. 177Lu-EDTMP: A potential therapeutic bone agent
3. Distribution of absorbed doses around point sources of electrons and beta particles in water and other media. MIRD pamphlet 7
4. 2DTPA) complexes
5. Synthesis of C-functionalized trans-cyclohexyldiethylene-triaminepentaacetic acids for labelling of monclonal antibodies with the bismuth-212 α-emitter
6. Targeting strategies for cancer radiotherapy
7. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies
8. 212Pb
9. Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N′,N″, N‴-tris(acetic acid)cyclododecane (PA-DOTA)
10. Effect of Mixed pendent groups on the solution and catalytic properties of europium(III) macrocyclic complexes: Bifunctional and monofunctional amide and alcohol pendents in septadentate or octadentate ligands
11. WO 89/12631
12. Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodection of human colon carcinoma xenografts
13. Synthesis of a kinetically stable Y-90 labeled macrocycle antibody conjugate
14. Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates
15. Health Phys
16. Protein and cell membrane iodinations with a sparingly soluble chloramide 1,3,4,6-tetrachloro-3a,6a-diphenyl-glycouril
17. Newer approaches to the radiolabeling of monoclonal antibodies by the use of metal chelates
18. Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody
19. Effective α-particle-mediated radioimmunotherapy of murine leukemia
20. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3
21. Generation, characterization and in vivo studies of humanized anticarcinoma antibody CC49
22. Clinical radioimmunotherapy
23. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
24. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: Critical factors in determining in vivo survival and organ toxicity
25. Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids: 1,4,7-triazacyclonoane-N,N′,N″-triacetic acid, 1,4,7,10-tetra-azacyclodecane-N,N′,N″,N‴-tetraacetic acid, and 1,4,8,11-tetra-azacyclodecane-N,N′,N″,N‴-tetraacetic acid
26. Equilibrium and kinetic studies of lanthanide complexes of macrocyclic polyamino carboxylates
27. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
28. Protein measurement with the folin phenol reagent
29. Kinetics and mechanisms of complex formation and ligand exchange
30. Physical parameters and biological stability of yttrium (III) diethylenetriaminepentaacetic acid derivative conjugates
31. Bioconjugate Chem
32. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49
33. The peptide way to macrocyclic bifunctional chelating-agents-synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″, N′-tetraacetic acid and study of its yttrium(III) complex
34. Organ distribution studies of lutetium-177 in mouse
35. 177Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma
36. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with tumor-associated glycoprotein 72 antigen
37. Metalloradiopharmaceuticals
38. Tumour targeting with radiolabelled macrocycle-antibody conjugate
39. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates
40. In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts
41. Biodistribution studies of indium- and yttrium-labeled MAb B72.3 using DTPA-derived bifunctional chelates
42. 177Lu)-labeled immunoconjugate
43. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates
44. Differential metabolic patterns of iodinated versus radiometal chelated anti-carcinoma sFv molecules
45. 213Bi-HuM195 (Anti-CD33) in patients with leukemia
46. Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides
47. A CDR-grafted (humanized) domain-deleted antitumor antibody
48. Biologic properties of chimeric CH1 domain-deleted and CH2 domain-deleted anti-carcinoma immunoglobulins
49. Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy
50. 131I
51. Samarium-153 and lutetium-177 chelation properties of selected macrocyclic and acyclic ligands
52. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3
53. Human colonic adenocarcinoma cells. Establishment and description of a new cell line
54. Metabolism of immunoglobulins
55. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma
56. Evaluation of methods for large scale preparation of antibody ligand conjugates
57. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA